Change abnormal gene expression BET inhibitor phase 2 clinical positive

Bone marrow fibrosis is a rare and serious bone marrow disease that disrupts the normal production of blood cells in the bodyThe patient's bone marrow is gradually replaced by fibrosis scar tissue, limiting the bone marrow's ability to produce blood cellsThe production of blood cells is transferred from the bone marrow to the spleen and liver, causing organ swellingPatients also experience symptoms such as extreme fatigue, shortness of breath, pain under the ribs, fever, night sweats, itching and bone painWhen bone marrow fibrosis occurs on its own, it is called primary bone marrow fibrosisSecondary bone marrow fibrosis occurs when too much red blood cell production (true erythema) or too much platelet production (primary platelet hyperplasia) evolves into bone marrow fibrosisCurrently, approved therapeutic drugs include JAK1/JAK2 inhibitor Jakafi (ruxolitinib) on the market in 2011 and JAK2 and FLT3 inhibitor inrebic (fedratinib) approved this yearConstellation's drug CPI-0610 is a selective BET inhibitor that inhibits BET, reduces the expression level of abnormalexpression genes, and achieves effects such as inhibiting the production of pro-inflammatory cytokinesCurrently, CPI-0610 is used in clinical trials as a single-drug therapy or in combination with JAK inhibitors for patients with bone marrow fibrosisConstellation believes that CPI-0610 has the potential to become a BET inhibitor of "Best-in-Class"'s working mechanism schematic of CPI-0610 (Photo: Resources 2)in phase 2 clinical studies called MANIFEST, patients with bone marrow fibrosis were divided into three queuesIn the 1/2 queue, patients who had previously developed resistance to resistance or intolerance to ruxolitinib received a single-drug treatment of CPI-0610 or a second-line treatment consisting of a combination of CPI-0610 and ruxolitinib, respectivelyAs of June 27, 2019, CPI-0610 showed good clinical activity in the treatment of patients with bone marrow fibrosispatients' spleen volume decreased, hemoglobin content increased, and the overall score of bone marrow fibrosis and disease symptoms improvedIn addition, four blood transfusion-dependent patients reached a state of non-dependence on blood transfusionsin the third queue, patients who had not previously been treated with JAK inhibitors received first-line treatment of the CPI-0610 and ruxolitinib combination therapies The trial data showed that the spleen volume of the 4 assessable patients decreased by at least 35%, and the syndrome syndrome syndrome score decreased by 50%, reaching the primary therapeutic end of the patient subgroup the company will present detailed trial data at this year's annual meeting of the American Society of Hematology " can show good clinical activity in patients who have not been treated with JAK inhibitors and for patients resistant to or intolerant of ruxolitinib Based on these positive data, we have increased the number of patients in the MANIFEST trial in the hope of seeing more comprehensive trial data," said Mr Jigar Raythaha, President and CEO of Constellation "
References: s1 , Constellation Pharmaceuticals Announces- And Nine-Month 2019 Financial Results, Retrieved November 6, 2019, https:// Epigenetic S for Cancer Patient, Retrieved November 6, 2019, from http://ir.constellationpharma.com/static-files/45aaf5b4-ddd9-4826-a289-982fb1d74f8e